Valproamide Tablets

This product is a broad-spectrum anti-epileptic drug. It has a fast onset of anti-epileptic effect, strong effect and low toxicity. Its mechanism of action has not been fully elucidated; it may be almost completely degraded into valproic acid by the action of intestinal microorganisms before entering the human circulation, and appear in the form of valproic acid in the blood. Experiments have confirmed that this product can increase the synthesis of gamma-aminobutyric acid (GABA) and reduce the degradation of GABA, thereby increasing the concentration of inhibitory neurotransmitter GABA, reducing the excitation of neurons and inhibiting seizures.

The active ingredient of this product is: valproamide. Chemical name: 2-propyl valeramide. Chemical structure: Molecular formula: C8H17NO Molecular weight: 143.2

This product is a sugar-coated tablet or a film-coated tablet, which appears white or off-white after removing the coating.

Drugs that regulate neurological disorders. Used to prevent and treat various types of epilepsy.

Oral administration: 0.6-1.2 g per day, divided into 3 doses. Children should take 10-30 mg/kg per day, divided into 2-3 doses.

1. In the early stage of treatment, dizziness, nausea, vomiting, drowsiness, fatigue, increased or decreased appetite and other reactions often occur, which generally disappear on their own. 2. It can cause changes in the menstrual cycle. 3. Less common are transient hair loss, headaches, allergies, hand tremors, frequent dreams, restlessness and irritability. 4. Long-term use may occasionally cause pancreatitis and acute liver necrosis. 5. It can reduce blood embroidery and cause purpura, bleeding and prolonged bleeding time. Blood counts should be checked regularly. 6. It has damage to liver function. Liver function should be checked after taking it for 2 months. 7. Occasionally there is unsteady walking, fixed vision, swollen eyes, tinnitus, and breast enlargement. 8. Occasionally there is hearing loss and reversible hearing damage.

1. Patients with a personal or family history of drug-induced jaundice are contraindicated. 2. Patients with liver disease or obvious liver damage are contraindicated.

Precautions for children: This product can accumulate in developing bones, so be careful. Precautions for pregnancy and lactation: This product can pass through the placenta. Animal experiments have reported that valproic acid is teratogenic. In clinical applications, breast enlargement and reduced lactation are occasionally seen. Pregnant women should weigh the pros and cons and use with caution. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

1 Drinking alcohol can increase the sedative effect. 2 When general anesthetics or central nervous system depressants are used in combination with valproic acid, the pharmacological effects of the former can be more obvious. 3 When used in combination with anticoagulants such as warfarin or heparin, as well as thrombolytics, the risk of bleeding increases. 4 When used in combination with aspirin or dipyridamole, the bleeding time can be prolonged due to reduced platelet aggregation. 5 When used in combination with phenobarbital, the metabolism of the latter slows down, and the blood concentration increases, thereby increasing the sedative effect and causing drowsiness. 6 When used in combination with primidone, it can also cause an increase in blood concentration and lead to poisoning. If necessary, the dosage of primidone needs to be reduced. 7 When used in combination with clonazepam to prevent absence seizures, there have been reports of a few cases in which absence seizures were induced. 8 When used in combination with phenytoin, there have been reports of cases inducing asterixis. Competition with protein binding can change the blood concentrations of both drugs. Since the concentration of phenytoin changes greatly, it needs to be measured frequently. However, whether the dosage needs to be adjusted depends on the clinical situation and blood drug concentration. 9 When used in combination with carbamazepine, the induction of liver enzymes will accelerate drug metabolism, which can reduce the blood drug concentration and half-life of both drugs. Therefore, the blood drug concentration must be monitored to determine whether the dosage needs to be adjusted. 10 When used in combination with drugs that are toxic to the liver, there is a potential risk of liver poisoning. 11 When used in combination with haloperidol, loxapine, maprotiline, monoamine oxidase inhibitors, phenothiazines, thioxanthenes and tricyclic antidepressants, it can increase the inhibition of the central nervous system, reduce the convulsion threshold and the effect of valproic acid, and the dosage must be adjusted in time to control seizures.

Sealed and light-proof.

0.2 g

Tentative 24 months

Hunan Xiangzhong Pharmaceutical Co., Ltd.

• Founded in:

  1998-03-05

• Address:

  No. 18, Daxing South Road, Baoqing Industrial Concentration Zone, Shaoyang City, Hunan Province

• Tax NO.:

  91430500185569358T

• Registered Funds:

  69 million yuan

• Website:

  Log in to view

• Email:

  Log in to view